Press release
Hodgkin Lymphoma Pipeline Report provides Therapeutic Assessment of the Key 10+ Pipeline Therapies in this Domain
For Hodgkin Lymphoma Emerging drugs, the Hodgkin Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Hodgkin Lymphoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Hodgkin Lymphoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Hodgkin Lymphoma clinical trials studies, Hodgkin Lymphoma NDA approvals (if any), and product development activities comprising the technology, Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Hodgkin Lymphoma Pipeline Report
• Over 10+ Hodgkin Lymphoma companies are evaluating 10+ Hodgkin Lymphoma pipeline therapies in various stages of development, and their anticipated acceptance in the Hodgkin Lymphoma market would significantly increase market revenue.
• The leading Hodgkin Lymphoma Companies include Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, Takeda, Seagen Inc, Merck Sharp & Dohme LLC, Millennium Pharmaceuticals, Inc, BeiGene, Jiangsu HengRui Medicine Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd, Novartis Pharmaceuticals, and others.
• Promising Hodgkin Lymphoma Pipeline Therapies include brentuximab vedotin, Penpulimab, Panobinostat, Carboplatin, Camrelizumab, Salvage Chemotherapy, Tislelizumab, Brentuximab Vedotin, gemcitabine, bendamustine, bleomycin, doxorubicin, and others.
• The Hodgkin Lymphoma Companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin Lymphoma R&D. The Hodgkin Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve Hodgkin Lymphoma.
Request a sample and discover the recent breakthroughs happening in the Hodgkin Lymphoma Pipeline landscape, visit here for Hodgkin Lymphoma Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/hodgkin-lmphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hodgkin Lymphoma Overview
Hodgkin Lymphoma also known as Hodgkin disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin's lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years.
Recent Developmental Activities in the Hodgkin Lymphoma Treatment Landscape
• In August 2021, HUTCHMED Limited and Epizyme, Inc. announced a collaboration to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
• Naratuximab emtansine (Debio 1562), an antibody-drug conjugate (ADC) targeting CD37, is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin's lymphomas (NHL).
• The development and planned commercialization of zandelisib are being conducted in partnership with Kyowa Kirin Co., Ltd. Zandelisib is being evaluated in multiple clinical studies by MEI Pharma, including COASTAL, a Phase III study, and TIDAL, a Phase II study, both of which are evaluating zandelisib in patients with relapsed and refractory follicular and marginal zone lymphomas.
• Polatuzumab vedotin (Anti-CD79b, DCDS4501A, RG7596), an antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against CD79b, link to the small molecule, cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE) is being developed by Genentech.
• 3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin late-stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment.
• Bristol-Myers Squibb, Pharmacyclics and Janssen Research & Development have entered into a collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).
For further information, refer to the detailed Hodgkin Lymphoma Drugs Launch, Hodgkin Lymphoma Developmental Activities, and Hodgkin Lymphoma News, click here for Hodgkin Lymphoma Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/hodgkin-lmphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hodgkin Lymphoma Emerging Drugs Profile
• AFM 13: Affimed Therapeutics
Affimed Therapeutics' new drug candidate, AFM 13, is a type of immunotherapy, currently in the development stage for the treatment of Hodgkin disease. Phase I data demonstrated good efficacy, and tolerability. The drug has been designated with orphan drug status. The drug does not kill cancer cells directly but encourages the body's own immune system to seek out and destroy the cells. It works by activating a type of immune cell, called a natural killer (NK) cell, and directing them to destroy the cancerous cells.
• Camidanlumab tesirine: ACD Therapeutics
ACD Therapeutics "breakthrough" drug carnidanlumab tesirine is currently being evaluated for the treatment of Hodgkin lymphoma and has demonstrated safety and efficacy in phase I trials. It is an antibody drug conjugate against CD25 expressed on the surface of cancerous cells.
Hodgkin Lymphoma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Hodgkin's Lymphoma. The companies which have their Hodgkin Lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Affimed Therapeutics and others.
Find out more about the Hodgkin Lymphoma Pipeline Segmentation, Therapeutics Assessment, Hodgkin Lymphoma Emerging Drugs, visit here for Hodgkin Lymphoma Treatment Landscape @ https://www.delveinsight.com/sample-request/hodgkin-lmphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hodgkin Lymphoma Pipeline Report
• Coverage- Global
• Hodgkin Lymphoma Companies- Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, Takeda, Seagen Inc, Merck Sharp & Dohme LLC, Millennium Pharmaceuticals, Inc, BeiGene, Jiangsu HengRui Medicine Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd, Novartis Pharmaceuticals, and others.
• Hodgkin Lymphoma Pipeline Therapies include brentuximab vedotin, Penpulimab, Panobinostat, Carboplatin, Camrelizumab, Salvage Chemotherapy, Tislelizumab, Brentuximab Vedotin, gemcitabine, bendamustine, bleomycin, doxorubicin, and others.
• Hodgkin Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Hodgkin Lymphoma Pipeline Companies and Therapies, click here for Hodgkin Lymphoma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hodgkin-lmphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hodgkin Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hodgkin Lymphoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Hodgkin Lymphoma Collaboration Deals
9. Mid Stage Products (Phase II)
10. AFM 13:Affimed Therapeutics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Camidanlumab tesirine: ACD Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Hodgkin Lymphoma Key Companies
19. Hodgkin Lymphoma Key Products
20. Hodgkin Lymphoma- Unmet Needs
21. Hodgkin Lymphoma- Market Drivers and Barriers
22. Hodgkin Lymphoma- Future Perspectives and Conclusion
23. Hodgkin Lymphoma Analyst Views
24. Hodgkin Lymphoma Key Companies
25. Appendix
Got Queries? Find out the related information on Hodgkin Lymphoma Mergers and acquisitions, Hodgkin Lymphoma Licensing Activities, just visit here for Hodgkin Lymphoma Recent Trends, and Future Perspectives @ https://www.delveinsight.com/sample-request/hodgkin-lmphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services
Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market
Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market
Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market
Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market
Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services
Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market
Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin Lymphoma Pipeline Report provides Therapeutic Assessment of the Key 10+ Pipeline Therapies in this Domain here
News-ID: 2989550 • Views: …
More Releases from DelveInsight Business Research
Urticaria Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Ap …
As per DelveInsight's assessment, globally, Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Urticaria Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market.
The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from…
Artificial Intelligence (AI) in Remote Patient Monitoring Market is expected to …
DelveInsight's "Artificial Intelligence (AI) in Remote Patient Monitoring Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Remote Patient Monitoring companies actively working in the market.
According to DelveInsight's analysis, The AI in Remote Patient Monitoring market, valued at USD 1,926.51 million in…
Artificial Intelligence (AI) in Precision Medicine Market is expected to reach U …
DelveInsight's "Artificial Intelligence (AI) in Precision Medicine Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Precision Medicine companies actively working in the market.
According to DelveInsight's analysis, The AI in Precision Medicine market, valued at USD 1,036.91 million in 2024, is expected…
AI in Diagnostics market is expected to reach USD 8,081.97 million by 2032 | Del …
DelveInsight's "Artificial Intelligence (AI) in Diagnostics Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Diagnostics companies actively working in the market.
DelveInsight Analysis: The AI in Diagnostics market, valued at USD 1,623.20 million in 2024, is projected to expand at a compound…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
